Profile of glucose lowering drug use in outpatients with type 2 diabetes mellitusPerfiles de hipoglicemiantes e insulinas en pacientes con diabetes mellitus tipo 2 y su efecto en control metabólico, hipoglicemia y otros efectos adversos

Simple item page
dc.article.numbere248451
dc.contributor.authorGrassi B.A.
dc.contributor.authorHernandez C.
dc.contributor.authorBoncompte M.
dc.contributor.authorHenriquez C.
dc.contributor.authorL'Huillier N.
dc.contributor.authorMiranda F.
dc.contributor.authorVrsalovic K.
dc.contributor.authorRosales V.
dc.date.accessioned2025-05-01T10:31:19Z
dc.date.available2025-05-01T10:31:19Z
dc.date.issued2022
dc.description.abstract© 2022 Sociedad Medica de Santiago. All rights reserved.Background: The use of glucose lowering agents with favorable weight profile is a growing practice in Diabetology. Aim: To characterize medication combinations in patients with type 2 Diabetes (T2D) and their effect on metabolic control. Material and Methods: Review of medical records of 249 outpatients with T2D with a median age of 66 years, cared for at a medical network. Clinical characteristics, glycated hemoglobin (HbA1c), details of Diabetes treatment (types of drugs or insulin), renal function, lipids and B12 vitamin levels were registered. Results: The median disease duration was 16 years. The most recent HbA1c was 7.4%. No patient was using sulfonylureas, 45 were using Dipeptidyl peptidase 4 inhibitors, 113 were using Sodium-glucose Cotransporter-2 (SGLT2i) Inhibitors, 21 used Glucagon-like Peptide-1 Receptor Agonists (GLP1ra), 158 used basal insulin and 61 on basal plus bolus insulin. The use of SGLT2i or GLP1ra was associated with a metabolic control similar to those patients not using them, while patients on rapid insulin had a significantly worse metabolic control and a tendency to greater body mass index. The use of basal insulin and rapid insulin was significantly associated with more hypoglycemia events. Conclusions: The use of SGLT2i and GLP1ra in patients with T2D is associated with better metabolic control than rapid insulin with less risk of hypoglycemia. The use of these therapies should be prioritized in the future.
dc.description.funder16.744 de Accidentes del Trabajo y Enfermedades Profesionales
dc.description.funderInnovación en Prevención de Accidentes y Enfermedades Profesionales 2014 de la Superintendencia de Seguridad Social
dc.format.extent13 páginas
dc.fuente.origenScopus
dc.identifier.doi10.4067/S0034-98872022001001334
dc.identifier.eisbn978-1-5106-5352-8
dc.identifier.eissn1542-7714
dc.identifier.isbn978-1-5106-5351-1
dc.identifier.issn07176163 00349887
dc.identifier.pubmedid40243597
dc.identifier.scieloidS0718-69242020000300109
dc.identifier.scopusidSCOPUS_ID:85160515555
dc.identifier.urihttps://doi.org/10.4067/S0034-98872022001001334
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/103741
dc.identifier.wosidWOS:001159473800015
dc.information.autorucEscuela de Medicina; Boncompte Guarda Mariana Paz; S/I; 119081
dc.information.autorucEscuela de Medicina; Grassi Corrales Bruno; 0000-0003-0095-9740; 132804
dc.issue.numero8
dc.language.isoes
dc.nota.accesoContenido completo
dc.pagina.final1341
dc.pagina.inicio1334
dc.relation.ispartofInternational Conference on Intelligent User Interfaces (30a. : 2025)
dc.revistaRevista Medica de Chile
dc.rightsacceso abierto
dc.subjectDiabetes Mellitus, Type 2
dc.subjectHypoglycemia
dc.subjectHypoglycemic Agents
dc.subject.ddc510
dc.subject.deweyMatemática física y químicaes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleProfile of glucose lowering drug use in outpatients with type 2 diabetes mellitusPerfiles de hipoglicemiantes e insulinas en pacientes con diabetes mellitus tipo 2 y su efecto en control metabólico, hipoglicemia y otros efectos adversos
dc.typeartículo
dc.volumen150
sipa.codpersvinculados119081
sipa.codpersvinculados132804
sipa.indexScopus
sipa.trazabilidadCarga WOS-SCOPUS;01-05-2025
Files
Collections
Artículos de revistas